| Curcumin: an inflammasome silencer S Hasanzadeh, MI Read, AR Bland, M Majeed, T Jamialahmadi, ... Pharmacological research 159, 104921, 2020 | 222 | 2020 |
| The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury AR Bland, FM Payne, JC Ashton, T Jamialahmadi, A Sahebkar Pharmacological Research 175, 105986, 2022 | 40 | 2022 |
| Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes S Radbakhsh, GE Barreto, AR Bland, A Sahebkar Biofactors 47 (4), 570-586, 2021 | 29 | 2021 |
| Inflammasomes and colorectal cancer SK Shahbaz, K Koushki, SHA Ayati, AR Bland, EE Bezsonov, A Sahebkar Cells 10 (2172), 2021 | 24 | 2021 |
| The effect of metformin in EML4-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models AR Bland, N Shrestha, RL Bower, RJ Rosengren, JC Ashton Biochemical Pharmacology 183, 114345, 2021 | 13 | 2021 |
| Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer AR Bland, RL Bower, M Nimick, BC Hawkins, RJ Rosengren, JC Ashton European Journal of Pharmacology 865, 172749, 2019 | 12 | 2019 |
| Does the mouse tail vein injection method provide a good model of lung cancer? N Shrestha, Z Lateef, O Martey, AR Bland, M Nimick, R Rosengren, ... F1000Research 8, 2019 | 8 | 2019 |
| Utilising fluorescent reporters to probe the mode of action of norbornen-7-one CO releasing molecules HM Johnston, JTB Kueh, RH Hartley, AR Bland, FM Payne, JC Harrison, ... Organic & Biomolecular Chemistry 20 (29), 5812-5819, 2022 | 7 | 2022 |
| Does crizotinib auto-inhibit CYP3A in vivo? AR Bland, N Shrestha, RJ Rosengren, JC Ashton Pharmacology 105 (11-12), 715-718, 2020 | 6 | 2020 |
| Synthesis and Biological Evaluation of (−) and (+)‐Spiroleucettadine and Analogues MP Badart, EM Barnes, AP Cording, SCL Gilmer, ID Billinghurst, ... ChemMedChem 16 (8), 1308-1315, 2021 | 3 | 2021 |
| Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK … N Shrestha, AR Bland, RL Bower, RJ Rosengren, JC Ashton Journal of Pharmacology and Experimental Therapeutics 374 (1), 134-140, 2020 | 3 | 2020 |
| Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors MA Berry, AR Bland, JC Ashton Scientific Reports 13 (1), 10041, 2023 | 2 | 2023 |
| Experimental determination of cancer drug targets with independent mechanisms of resistance AR Bland, N Shrestha, M Berry, C Wilson, JC Ashton Current Cancer Drug Targets 22 (2), 97-107, 2022 | 1 | 2022 |
| P2. 14-66 Combination ALK and MEK Inhibition in ALK-Positive Lung Cancer J Ashton, N Shrestha, A Bland Journal of Thoracic Oncology 14 (10), S857, 2019 | 1 | 2019 |
| EP02. 01-01 Differing Cell Cycle Responses for Alectinib and SHP099 in Variant 1 and Variant 3 ALK+ Non-Small Cell Lung Cancer Cell Lines M Berry, A Bland, J Ashton Journal of Thoracic Oncology 18 (11), S424-S425, 2023 | | 2023 |
| Treatment with lorlatinib induced hypercholesterolemia with PCSK9 inhibitors; A new solution to an emerging need in non-small cell lung cancer therapy. JC Ashton, AR Bland, IA Sammut Open Journal Clinical and Medical Case Reports 9, 2023 | | 2023 |
| Tumour cell suppression by spiroleucettadine through dual regulation of cell cycle and apoptosis B Watts, M Berry, A Bland, M Badart, B Hawkins, J Ashton F1000Research 11, 1328, 2022 | | 2022 |
| The cardioprotective agent oCOm-21 inhibits NLRP3 inflammasome assembly in cardiac ischaemia reperfusion injury. AR Dabb, SH Thwaite, FM Payne, AR Bland, JC Harrison, IA Sammut Otago Medical School Research Society, 2022 | | 2022 |
| Considerations for Whole-Slide Analysis of Murine Xenografts Experiments AR Bland, JC Ashton Journal of Histochemistry & Cytochemistry 69 (10), 627-631, 2021 | | 2021 |
| Repurposing the hypoglycemic agent, metformin, for targeted lung cancer AR Bland, N Shrestha, RL Bower, RJ Rosengren, JC Ashton New Zealand Medical Association, 2021 | | 2021 |
